Author/Authors :
Samadi-Shams, Sara tabriz university of medical sciences - School of Advanced Biomedical Sciences, Research Center for Pharmaceutical Nanotechnology, ايران , Samadi-Shams, Sara IFOM-IEO Campus - European Institute of Oncology - Department of Experimental Oncology, Italy , Atashpaz, Sina tabriz university of medical sciences - School of Advanced Biomedical Sciences, Research Center for Pharmaceutical Nanotechnology, ايران , Atashpaz, Sina IFOM-IEO Campus - European Institute of Oncology - Department of Experimental Oncology, Italy , Khani, Sajjad tabriz university of medical sciences - School of Advanced Biomedical Sciences, Research Center for Pharmaceutical Nanotechnology, ايران
Abstract :
Introduction: Recent report on existence of a stem region of hemagglutinin has arisen new hopes for vaccination of influenza A as it consist of a conserve fusion peptide shared across several influenza subtypes and can be targeted by human immune system. Methods: Given that traditional vaccination based on live attenuated viruses often fails to surpass such viral infection, a great deal of attention has been devoted to develop a safe yet efficient system for vaccination influenza A. We believe that a natural bioshuttle can be recruited for spontaneous mass vaccination. Results: Thus, here, we hypothesize that a bioengineered transgenic Hirudo medicinalis can be considered as an alive bioshuttle for in-situ vaccination against influenza A virus. By introducing the designated gene(s) encoding the target fragment (i.e., stem region of hemagglutinin), this microsurgeon can act as a rapid microproducer of viral proteins for in-house mass vaccination through imparting the necessary proteins such as those, naturally presented in leech s saliva. Conclusion: This peculiar bioshuttle can be easily exploited as a medical modality choice at home resulting in greater patient compliance.
